

**To:** [REDACTED] [REDACTED]@minvws.nl]  
**Cc:** [REDACTED] [REDACTED]@5.1.2e.com]; [REDACTED] [REDACTED]@roche.com]; [REDACTED]  
 [REDACTED] [REDACTED]@roche.com]; [REDACTED] [REDACTED]@roche.com]  
**From:** [REDACTED]  
**Sent:** Sun 9/6/2020 9:45:13 PM  
**Subject:** Re: Roche Supply - Follow-up  
**Received:** Sun 9/6/2020 9:45:57 PM

Dear [REDACTED]

Thank you for your reply and I am more than happy to have another discussion in late October. This can be coordinated through [REDACTED] and we should have more clarity surrounding our scale-up efforts at that time. I do appreciate your patience and your willingness to work with Roche as we tackle this terrible pandemic together. Also, I believe the antigen test is going to be a valuable part of the overall testing solution and it is good to know that evaluations are planned.

I wish you the very best and look forward to staying in touch.

[REDACTED]

[REDACTED]  
 [REDACTED]

Roche Diagnostics International Ltd.  
 Forrenstrasse 2

CH-6343 Rotkreuz  
 Switzerland

Phone: [REDACTED]  
 mobile: [REDACTED]  
 [REDACTED]@roche.com  
[www.roche-rotkreuz.com](http://www.roche-rotkreuz.com)

[REDACTED]

On Fri, Sep 4, 2020 at 6:00 AM [REDACTED] <[REDACTED]@minvws.nl> wrote:

Dear [REDACTED]

Thanks for your enlarged offer. We discussed your offer with [REDACTED] yesterday and of course with our Minister. [REDACTED] explained your efforts and constraints at the moment, but also offered the opportunity to discuss again a little later in time. So we do

[REDACTED]

It would be of great significance to us if we can discuss the offer at the end of oktober again – regarding changing circumstances and regard by then the possibility of [REDACTED] starting November and [REDACTED] in January.

We also discussed the anti-gen testing yesterday. We are definitely interested, but a validation by RIVM is of importance to us.

[REDACTED] RIVM will come into contact with you on this.

Met vriendelijke groet,

[REDACTED]

[REDACTED]

5.1.2e @minvws.nl

5.1.2e

Secretariaat:

5.1.2e

5.1.2e

**Van:** 5.1.2e <5.1.2e@roche.com>

**Verzonden:** dinsdag 25 augustus 2020 17:58

**Aan:** 5.1.2e <5.1.2e@5.1.2e.com>; 5.1.2e <5.1.2e@minvws.nl>

**CC:** 5.1.2e <5.1.2e@roche.com>; 5.1.2e <5.1.2e@roche.com>; 5.1.2e <5.1.2e@roche.com>; 5.1.2e <5.1.2e@roche.com>

**Onderwerp:** Roche Supply - Follow-up

Dear 5.1.2e

Thanks again for the opportunity to connect with you last week regarding product supply for the Netherlands which is vitally important to all of us. I have thought deeply about a solution recognizing that there is indeed a massive shortage of high quality molecular tests and achieving great scale takes precious time. With that in mind, we can do the following;

I trust you recognize that there are lots of individual items that need to come together to meet these targets and also ask for your patience as we work to scale.

As always, I am happy to further discuss but this is the best I can offer right now.

With best regards,

5.1.2e

5.1.2e

5.1.2e

**Roche Diagnostics International Ltd.**  
Forrenstrasse 2

CH-6343 Rotkreuz  
Switzerland

Phone: [REDACTED] 5.1.2e  
mobile: [REDACTED] 5.1.2e  
[REDACTED] 5.1.2e [@roche.com](mailto:[REDACTED]@roche.com)  
[www.roche-rotkreuz.com](http://www.roche-rotkreuz.com)

[REDACTED] 5.1.2e